Rating Change
UBS analysts reiterated a Buy rating on MapLight Therapeutics, Inc. (NASDAQ:MPLT) on July 21, 2026.
reiterateNASDAQ:MPLT
UBS Reiterates Buy Rating on MapLight Therapeutics, Inc. (MPLT)
Rating Change UBS analysts reiterated a Buy rating on MapLight Therapeutics, Inc. (NASDAQ:MPLT) on July 21, 2026. Market Context MapLight Therapeutics, Inc.
Market Context
MapLight Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $37.44 with a market capitalization of $15.9M.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for MapLight Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for MapLight Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | UBS | Buy | N/A |
| Jul 21, 2026 | BMO Capital | Outperform | N/A |
| Jul 10, 2026 | Needham | Buy | N/A |
| Jun 25, 2026 | Raymond James | Strong Buy | N/A |
| Jun 23, 2026 | Craig-Hallum | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MPLT Stock Page
Frequently Asked Questions
What does a Buy rating mean for MPLT?
A Buy rating from UBS reflects the analyst's outlook on MapLight Therapeutics, Inc. (NASDAQ:MPLT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MPLT forecast page.